The 3 most recent market catalysts affecting $RZLT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 24, 2026
Corporate Catalyst
Bearish
Impact 92
Rezolute Q4 EPS $(0.20) Misses $(0.15) Estimate
Rezolute announced its Q4 earnings, reporting a loss of $(0.20) per share, which was 33.33% worse than the analyst consensus estimate of $(0.15). This significant miss indicates th…
Sep 9, 2026
Corporate Catalyst
Bearish
Impact 85
Rezolute shares are trading lower after the company announced that data from the Phase 3 sunRIZE study still remains under review by the FDA.
This headline is a significant corporate catalyst for Rezolute (RZLT) as it directly impacts the company's primary drug candidate. The continued FDA review, rather than an approval…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 65
Rezolute Said FDA Is Still Reviewing Ersodetug Submission In Congenital Hyperinsulinism; The Company Continues To Await Feedback And Reserves The Ability To Request Formal Meeting Under Regulatory Timeline
Rezolute's 8-K filing indicates that the FDA is still reviewing the Ersodetug submission for congenital hyperinsulinism, and the company is awaiting feedback. This update suggests …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.